#USA #New York #Investor Rights #Rosen Law Firm #Ultragenyx

Overview of the Ultragenyx Securities Fraud Lawsuit

The Rosen Law Firm, a globally recognized law firm dedicated to protecting investor rights, has reached out to purchasers of common stock in Ultragenyx Pharmaceutical Inc., specifically those who invested between August 3, 2023, and December 26, 2025. The firm is urging these investors to consider participating in a class action lawsuit that addresses significant allegations of securities fraud against the company.

Why Participate?

This potential lawsuit arises from allegations that Ultragenyx misled investors regarding the efficacy and testing outcomes of its treatment product, setrusumab (UX 143), specifically associated with Osteogenesis Imperfecta (OI). The Rosen Law Firm emphasizes that investors who purchased shares during the specified time frame may be eligible for compensation, and participation involves no out-of-pocket costs due to a contingency fee arrangement.

Important Deadlines

The firm has set a critical deadline for class action participants to file as lead plaintiffs by April 6, 2026. This role is crucial as a lead plaintiff represents the interests of the entire class, guiding the litigation process. Interested investors can find more information on how to join the class action by visiting their official website or contacting their office directly.

Details of the Allegations

The lawsuit centers around claims that Ultragenyx provided investors with overly optimistic projections regarding the outcomes of their Phase III Orbit and Cosmic studies for setrusumab. These studies aimed to demonstrate that the drug could significantly reduce the annualized fracture rate in patients suffering from OI. However, the suit alleges that these optimistic assertions were based on misleading information and did not adequately disclose the inherent risks involved in the studies. More critically, while the drug increased bone density, there was no guaranteed correlation to an actual decrease in fracture rates.

The lawsuit alleges that Ultragenyx’s public statements misled shareholders about the true status of the drug’s trials, resulting in investors purchasing stocks at inflated prices without a clear understanding of the associated risks.

The Rosen Law Firm's Track Record

In the realm of securities class actions, the Rosen Law Firm stands out for its history of successful litigations. The firm has achieved landmark settlements, including the largest-ever securities class action against a Chinese company, solidifying its reputation and capability. Investors are urged to be prudent in selecting legal representation; the Rosen Law Firm not only has a proven track record but is also known for its commitment to representing shareholders’ interests vigorously.

How to Get Involved

For investors looking to participate, the process to join the class action is straightforward. Interested parties are encouraged to visit Rosen Legal for detailed instructions on submitting a claim. Alternatively, they can reach out via telephone to speak with Phillip Kim, Esq., for more personalized guidance.

Conclusion

While participating in a class action may seem daunting, it offers an opportunity for those affected by corporate malfeasance to seek justice and potentially recover losses incurred due to misleading practices. With firm guidance and strong legal representation, investors can navigate this process and contribute to a collective push for accountability from Ultragenyx Pharmaceutical Inc.

Stay informed about further developments by following the Rosen Law Firm on their social media platforms or checking their official site for announcements regarding the lawsuit’s progress. This is an opportunity for Ultragenyx shareholders to unite and assert their rights, paving the way for transparency and integrity in corporate practices.